Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study

References

• Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849-57
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-19
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-92
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-80
   PubMed Web of Science ®Google Scholar
• Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449-72
   PubMed Web of Science ®Google Scholar
• Wu JR, Liou SF, Lin SW, et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59:48-56
   PubMed Web of Science ®Google Scholar
• Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1:173-82
   PubMedGoogle Scholar
• Beckey C, Lundy A, Lutfi N. Lercanidipine in the treatment of hypertension. Ann Pharmacother 2007;41:465-73
   PubMed Web of Science ®Google Scholar
• Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011;31:561-7
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004;17:259-66
   PubMedGoogle Scholar
• Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;27:73-80
   PubMed Web of Science ®Google Scholar
• Srivastava V, Kan G, Manickam V, Dua R. Lercanidipine induced acute interstitial nephritis, never reported before. Nephrology 2013;18(Suppl S1):71 abstr. 224
   Google Scholar
• Chan DC, Chang CH, Lim LC, et al. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int 2016;27:2855-65
   PubMed Web of Science ®Google Scholar
• Lin TY, Chen YG, Lin CL, et al. Inflammatory bowel disease increases the risk of peripheral arterial disease: a nationwide cohort study. Medicine (Baltimore) 2015;94:e2381
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Herzog C, et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009;53(1 Suppl):S1-S374
   PubMed Web of Science ®Google Scholar
• Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173-82
   PubMed Web of Science ®Google Scholar
• Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014;85:1200-7
   PubMed Web of Science ®Google Scholar
• Bergstralh EKJ. SAS Macros: gmatch: Divison of Biomedical Statistics and Informatics. 2003. Available at: http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros?_ga=1.31249471.1656432288.1477897281 [Last accessed 6 January 2017]
   Google Scholar
• Carlson MD, Morrison RS. Study design, precision, and validity in observational studies. J Palliat Med 2009;12:77-82
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease – six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50
   PubMed Web of Science ®Google Scholar
• Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Iwakiri K, Sugiura T, Kobayashi M. Effect of nifedipine administration (10 mg) on esophageal acid exposure time. J Gastroenterol 2000;35:43-6
   PubMed Web of Science ®Google Scholar
• Lavy A. Corrosive effect of nifedipine in the upper gastrointestinal tract. Diagn Ther Endosc 1999;6:39-41
   PubMedGoogle Scholar
• Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke 2011;42:2860-5
   PubMed Web of Science ®Google Scholar
• Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs 1999;8:1043-62
   PubMedGoogle Scholar
• Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin–angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens 2008;21:1076-85
   PubMed Web of Science ®Google Scholar
• Di Somma S. Importance of rapid and effective reduction of blood pressure in treating hypertension for the prevention of cardiovascular diseases: a lesson from the VALUE study. High Blood Press Cardiovasc Prev 2005;12:135-40
   PubMedGoogle Scholar
• Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-73
   PubMed Web of Science ®Google Scholar
• Ozdemir O, Erbas B, Ugur O, et al. Scintigraphic evaluation of the short- and long-term renal effects of oral felodipine using technetium-99m-mercaptoacetyl triglycine. Am J Nephrol 1993;13:249-54
   PubMed Web of Science ®Google Scholar
• Chintala MS, Jandhyala BS. Evaluation of the efficacy of felodipine in two models of acute renal failure in dogs. Kidney Int Suppl 1992;36:S94-S9
   PubMedGoogle Scholar
• Elmfeldt D, Nordlander M, Edgar B. Renal effects of felodipine – a review. Kidney Int Suppl 1992;36:S54-S60
   PubMedGoogle Scholar
• Yang WC, Hwang SJ, Taiwan Society of N. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 2008;23:3977-82
   PubMed Web of Science ®Google Scholar
• Valderrabano F, Gomez-Campdera F, Jones EH. Hypertension as cause of end-stage renal disease: lessons from international registries. Kidney Int Suppl 1998;68:S60-S6
   PubMed Web of Science ®Google Scholar